Study: Zoledronic acid inhibits bone growth

04/25/2013 | AAFP News Now

Researchers found osteoporosis drug zoledronic acid increases levels of a biomarker that inhibits bone formation in postmenopausal women. The study was published in the Journal of Clinical Endocrinology & Metabolism. Lead author Antonino Catalano, M.D., said patients who use zoledronic acid may need other treatments to allow for new bone formation.

View Full Article in:

AAFP News Now

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR